HEATHER PENNIMAN: Open Payments
NPI 1134648918 · NORTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$401 in 21 payments from 15 companies in 2025. Trend: 2023 $112 · 2024 $0 · 2025 $401
Food & beverage: $401
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Merck Sharp & Dohme LLC | 2 | $41 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
| Novo Nordisk Inc | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| ABBVIE INC. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
Products named: Kerendia, CAPLYTA, VERQUVO, BREZTRI, ELIQUIS, JARDIANCE, QULIPTA, Veozah.
Industry payments across VA — which companies pay providers there.
